CN111732660B - 骨髓间充质干细胞和单克隆抗体联合治疗癌症 - Google Patents
骨髓间充质干细胞和单克隆抗体联合治疗癌症 Download PDFInfo
- Publication number
- CN111732660B CN111732660B CN202010754816.9A CN202010754816A CN111732660B CN 111732660 B CN111732660 B CN 111732660B CN 202010754816 A CN202010754816 A CN 202010754816A CN 111732660 B CN111732660 B CN 111732660B
- Authority
- CN
- China
- Prior art keywords
- cells
- monoclonal antibody
- mesenchymal stem
- stem cells
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/868—Vaccine for a specifically defined cancer kidney
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Epidemiology (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Developmental Biology & Embryology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Mycology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Zoology (AREA)
Abstract
Description
名称 | 缓冲体系 | 浓度mg/ml | 体积ml | 总量mg | 纯度 |
512C | 0.01M PBS | 1.9 | 5.0 | 9.5 | >97% |
组别 | 细胞个数 |
实验组 | 29.11±3.46 |
对照组1 | 39.22±8.53 |
对照组2 | 71.59±14.17 |
阴性对照组 | 118.17±12.88 |
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010754816.9A CN111732660B (zh) | 2020-07-31 | 2020-07-31 | 骨髓间充质干细胞和单克隆抗体联合治疗癌症 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010754816.9A CN111732660B (zh) | 2020-07-31 | 2020-07-31 | 骨髓间充质干细胞和单克隆抗体联合治疗癌症 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111732660A CN111732660A (zh) | 2020-10-02 |
CN111732660B true CN111732660B (zh) | 2020-12-29 |
Family
ID=72656653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010754816.9A Active CN111732660B (zh) | 2020-07-31 | 2020-07-31 | 骨髓间充质干细胞和单克隆抗体联合治疗癌症 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111732660B (zh) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115975036B (zh) * | 2022-08-18 | 2023-06-09 | 北京诺赛国际医学研究院 | 包含干细胞的药物组合物及其治疗癌症的用途 |
CN115806935B (zh) * | 2022-08-26 | 2023-07-07 | 厦门莫森凯尔细胞生物科技有限公司 | 脐带间充质干细胞培养方法 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0366707A1 (en) * | 1987-05-06 | 1990-05-09 | OOSTERWIJK, Egbert | Monoclonal antibodies to renal cell carcinoma |
FR2793497B1 (fr) * | 1999-05-10 | 2003-04-18 | Centre Nat Rech Scient | Anticorps monoclonal dirige contre les cellules de carcinome renal humain |
US20090191119A1 (en) * | 2008-01-28 | 2009-07-30 | Young David S F | Cancerous disease modifying antibodies |
CN102875676B (zh) * | 2011-07-13 | 2014-11-05 | 无锡天演生物技术有限公司 | 全人源抗人vegf单抗分子及其应用 |
-
2020
- 2020-07-31 CN CN202010754816.9A patent/CN111732660B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN111732660A (zh) | 2020-10-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111671896B (zh) | 骨髓间充质干细胞和单克隆抗体联合治疗癌症的用途 | |
CN111732660B (zh) | 骨髓间充质干细胞和单克隆抗体联合治疗癌症 | |
CN112679613B (zh) | 骨髓间充质干细胞联合单克隆抗体治疗癌症中的用途 | |
CN113444169A (zh) | 新型冠状病毒的人源单克隆抗体及其应用 | |
CN112521502A (zh) | 一种抗IL-13Rα2的纳米抗体及其编码序列和应用 | |
US10961533B2 (en) | Stem cell with suppressed SOCS and improved immunosuppressive ability and use thereof | |
CN110747163A (zh) | 一种提高人脂肪间充质干细胞成脂分化的方法及其专用培养基 | |
CN115028730B (zh) | 一种成体干细胞衍生的类器官制备方法 | |
CN112725268B (zh) | 一种促进脂肪干细胞成骨分化的组合物及其应用 | |
CN111793134A (zh) | 一种用于癌症治疗中的药物、肿瘤疫苗及抑制剂 | |
AU2020342139B2 (en) | Novel micropeptide HMMW and application thereof | |
CN117050183A (zh) | 一种ptn-ptprz1通路的阻断抗体及其在胶质瘤靶向治疗的应用 | |
CN112553156B (zh) | 一种有效提高骨髓间充质干细胞细胞因子生产的方法 | |
CN112745389A (zh) | 结合人il-5的单克隆抗体及其应用 | |
CN109337903A (zh) | 一种长链非编码RNA lncRNA-6585及其抗体与应用 | |
CN110357946B (zh) | 一种抑制肿瘤转移的多肽及其应用 | |
KR20220113589A (ko) | 신장 질환의 예방 또는 치료용 조성물 | |
CN115894681B (zh) | 一种用于间充质干细胞分化的制剂 | |
CN112920994B (zh) | 一种促进干细胞细胞因子产量的生产方法 | |
Xu et al. | Monoclonal antibodies to αI spectrin Src homology 3 domain associate with macropinocytic vesicles in nonerythroid cells | |
CN111116750B (zh) | 一种特异性靶向胆管癌干细胞的单克隆抗体及其应用 | |
CN114539403B (zh) | 靶向人bcma蛋白的兔重组单克隆抗体及应用 | |
CN113308491B (zh) | 一种共表达nfat和人dnam-1蛋白的重组质粒、重组细胞及其构建方法和应用 | |
Li et al. | Neural differentiation of adipose-derived stem cells by indirect co-culture with Schwann cells | |
JP4117054B2 (ja) | 抗体及びその製法、この抗体を産生する融合細胞及びその製法、並びにこの抗体に認識される抗原蛋白質 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Li Hongchen Inventor after: Kou Jialin Inventor after: Zhang Yongqiang Inventor after: Li Jiuxia Inventor after: Liu Huan Inventor after: Zhu Xiaoming Inventor before: Liu Huan Inventor before: Zhu Xiaoming |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20201208 Address after: 050000, 1, 02, 01 and 04, building 3, A District, Hebei science and Technology Park, Shijiazhuang hi tech Zone, Zhejiang Province Applicant after: HEBEI YOUREN BIOTECHNOLOGY Co.,Ltd. Applicant after: Beijing Youren Biotechnology Group Co.,Ltd. Applicant after: Qinhuangdao Youren Biotechnology Co.,Ltd. Address before: 701-286, floor 7, building 1, No. 5, guangyuanzha, Haidian District, Beijing 100081 Applicant before: Beijing Guangwei Biotechnology Co.,Ltd. |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
PP01 | Preservation of patent right | ||
PP01 | Preservation of patent right |
Effective date of registration: 20220811 Granted publication date: 20201229 |